Pluristyx, the leading provider of innovative induced pluripotent stem cells (iPSC), announces the issuance of the groundbreaking induced Allogeneic Cell Tolerance (iACT Stealthtm) U.S. Patent No. 12, ...
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
The human body is a key subject of research by scientists worldwide. A biomedical engineering research team led by Professor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback